NCT04263909View on ClinicalTrials.gov

The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

199

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

April 1, 2022

Study Completion Date

December 30, 2023

Conditions

Spine FusionPain, PostoperativeOpioid Use

Interventions

DRUG

Sublingual Tablet

sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04263909 - The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients | Biotech Hunter | Biotech Hunter